{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T11:35:04Z","timestamp":1791200104810,"version":"4.2.0"},"reference-count":57,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1097\/aci.0b013e3283630cc2","type":"journal-article","created":{"date-parts":[[2013,6,25]],"date-time":"2013-06-25T14:22:37Z","timestamp":1372170157000},"page":"330-336","source":"Crossref","is-referenced-by-count":41,"title":["Toxic epidermal necrolysis"],"prefix":"10.1097","volume":"13","author":[{"given":"Haur-Yueh","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Hung","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20210128","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1056\/NEJM199512143332404","article-title":"Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis.","volume":"333","author":"Roujeau","year":"1995","journal-title":"N Engl J Med"},{"key":"R2-4-20210128","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.jid.5701033","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR study.","volume":"128","author":"Mockenhaupt","year":"2008","journal-title":"J Invest Dermatol"},{"key":"R4-4-20210128","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJM199411103311906","article-title":"Severe adverse cutaneous reactions to drugs.","volume":"331","author":"Roujeau","year":"1994","journal-title":"N Engl J Med"},{"key":"R5-4-20210128","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/428486a","article-title":"Medical genetics: a marker for Stevens-Johnson syndrome.","volume":"428","author":"Chung","year":"2004","journal-title":"Nature"},{"key":"R6-4-20210128","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jdermsci.2012.04.002","article-title":"Recent advances in the genetics and immunology of Stevens-Johnson syndrome and toxic epidermal necrolysis.","volume":"66","author":"Chung","year":"2012","journal-title":"J Dermatol Sci"},{"key":"R7-4-20210128","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/sj.tpj.6500356","article-title":"A marker for Stevens-Johnson syndrome : ethnicity matters.","volume":"6","author":"Lonjou","year":"2006","journal-title":"Pharmacogenomincs J"},{"key":"R8-4-20210128","doi-asserted-by":"crossref","first-page":"579","DOI":"10.4103\/0378-6323.57718","article-title":"Association of HLA-B1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians.","volume":"75","author":"Mehta","year":"2009","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R9-4-20210128","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1111\/j.1528-1167.2010.02766.x","article-title":"HLA-B1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients.","volume":"51","author":"Kaniwa","year":"2010","journal-title":"Epilepsia"},{"key":"R10-4-20210128","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/j.1528-1167.2010.02533.x","article-title":"Association between HLA-B1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population.","volume":"51","author":"Tassaneeyakul","year":"2010","journal-title":"Epilepsia"},{"key":"R11-4-20210128","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1528-1167.2009.02269.x","article-title":"HLA class I markers in Japanese patients with carbamazepine-induced cutaneous adverse reactions.","volume":"51","author":"Ikeda","year":"2010","journal-title":"Epilepsia"},{"key":"R12-4-20210128","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/01.fpc.0000199500.46842.4a","article-title":"Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions.","volume":"16","author":"Hung","year":"2006","journal-title":"Pharmacogenet Genomics"},{"key":"R13-4-20210128","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1093\/hmg\/ddq537","article-title":"Genome-wide association study identified HLA-A3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reaction in Japanese population.","volume":"20","author":"Ozeki","year":"2011","journal-title":"Hum Mol Genet"},{"key":"R14-4-20210128","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1056\/NEJMoa1013297","article-title":"HLA-A3101 and carbamazepine-induced hypersensitivity reactions in Europeans.","volume":"364","author":"McCormack","year":"2011","journal-title":"N Eng J Med"},{"key":"R16-4-20210128","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1111\/j.1528-1167.2007.01022.x","article-title":"Association between HLA-B1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese.","volume":"48","author":"Man","year":"2007","journal-title":"Epilepsia"},{"key":"R17-4-20210128","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2217\/pgs.09.162","article-title":"Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese.","volume":"11","author":"Hung","year":"2010","journal-title":"Pharmacogenomics"},{"key":"R18-4-20210128","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.eplepsyres.2010.10.006","article-title":"Association study of lamotrigine-induced cutaneous adverse reactions and HLA-B1502 in a Han Chinese population.","volume":"92","author":"An","year":"2010","journal-title":"Epilepsy Res"},{"key":"R19-4-20210128","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1073\/pnas.0409500102","article-title":"HLA-B5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurnol.","volume":"102","author":"Hung","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R20-4-20210128","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/FPC.0b013e328330a3b8","article-title":"Strong association between HLA-B5801 and allopurinol induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population.","volume":"19","author":"Tassaneeyakul","year":"2009","journal-title":"Pharmmacogent Genomics"},{"key":"R21-4-20210128","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/FPC.0b013e32834282b8","article-title":"Positive and negative associations of HLA class 1 alleles with allopurinol-induced SCARs in Koreans.","volume":"21","author":"Kang","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"R22-4-20210128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ndt\/gfr060","article-title":"HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency.","volume":"26","author":"Jung","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"R23-4-20210128","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/FPC.0b013e3282f3ef9c","article-title":"A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs.","volume":"18","author":"Lonjou","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"R24-4-20210128","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.2217\/14622416.9.11.1617","article-title":"HLA-B locus in Japanese patients with antiepileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis.","volume":"9","author":"Kaniwa","year":"2008","journal-title":"Pharmacogenomics"},{"key":"R25-4-20210128","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/1471-2350-12-118","article-title":"Association of HLA-B5801 allele and allopurinl-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis.","volume":"12","author":"Somkrua","year":"2011","journal-title":"BMC Med Genet"},{"key":"R26-4-20210128","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/tpj.2011.41","article-title":"A whole-genome association study of major determinants for allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients.","volume":"13","author":"Tohkin","year":"2013","journal-title":"Pharmacogenomics"},{"key":"R27-4-20210128","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1750-1172-6-52","article-title":"Genome-wide association study of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe.","volume":"6","author":"Genin","year":"2011","journal-title":"Orphanet J Rare Dis"},{"key":"R28-4-20210128","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.eplepsyres.2011.08.010","article-title":"Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans.","volume":"97","author":"Kim","year":"2011","journal-title":"Epilepsy Res"},{"key":"R29-4-20210128","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1097\/FPC.0b013e32832c347d","article-title":"High-resolution HLA genotyping and severe cutaneous adverse reactions in lamotrigine-treated patients.","volume":"19","author":"Kazeem","year":"2009","journal-title":"Pharmacogenet Genomics"},{"key":"R30-4-20210128","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2217\/pgs.10.54","article-title":"HLA-B5901 is strongly associated with methazolamide-induced Stevens-Johnson syndrometoxic epidermal necrolysis.","volume":"11","author":"Kim","year":"2010","journal-title":"Pharmacogenomics"},{"key":"R31-4-20210128","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1001\/archderm.1987.01660330082014","article-title":"Genetic susceptibility to toxic epidermal necrolysis.","volume":"123","author":"Roujeau","year":"1987","journal-title":"Arch Dermatol"},{"key":"R32-4-20210128","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1111\/j.1528-1167.2008.01719.x","article-title":"Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-b1502 allele in Thai population.","volume":"49","author":"Locharernkul","year":"2008","journal-title":"Epilepsia"},{"key":"R33-4-20210128","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1016\/j.jaci.2011.12.990","article-title":"Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome.","volume":"129","author":"Wei","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"R34-4-20210128","first-page":"548","article-title":"Immune self-reactivity triggered by drug-modified HLA-peptide repertoire.","volume":"486","author":"Illing Pt, Vivian","year":"2012","journal-title":"Nature"},{"key":"R35-4-20210128","doi-asserted-by":"crossref","first-page":"9959","DOI":"10.1073\/pnas.1207934109","article-title":"Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire.","volume":"109","author":"Ostrov","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R36-4-20210128","doi-asserted-by":"crossref","first-page":"F21","DOI":"10.1097\/QAD.0b013e328355fe8f","article-title":"Abacavir induces loading of novel self-peptides into HLA-B5701: an autoimmune model for HLA associated drug hypersensitivity.","volume":"26","author":"Norcross","year":"2012","journal-title":"AIDS"},{"key":"R37-4-20210128","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1046\/j.1365-2249.2000.01119.x","article-title":"Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer (NK) inhibitory receptors.","volume":"119","author":"Le Cleach","year":"2000","journal-title":"Clin Exp Immunol"},{"key":"R38-4-20210128","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/nm.1884","article-title":"Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis.","volume":"14","author":"Chung","year":"2008","journal-title":"Nature Med"},{"key":"R39-4-20210128","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.jaci.2011.08.013","article-title":"Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome.","volume":"128","author":"Ko","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"R40-4-20210128","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1111\/j.1365-2133.2009.09627.x","article-title":"Differential gene expression in drug hypersensitivity reactions: induction of alarmins in severe bullous diseases.","volume":"162","author":"Bellon","year":"2010","journal-title":"Br J Dermatol"},{"key":"R41-4-20210128","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/j.1398-9995.2010.02484.x","article-title":"Expression of -defensin 1-3 in T cells from severe cutaneous drug-induced hypersensitivity reactions.","volume":"66","author":"Morel","year":"2011","journal-title":"Allergy"},{"key":"R42-4-20210128","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.jaci.2009.10.030","article-title":"CD945NKG2C is a killer effector molecule in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis.","volume":"125","author":"Morel","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"R43-4-20210128","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.2217\/pgs.12.108","article-title":"HLA and pharmacogenetics of drug hypersensitivity.","volume":"13","author":"Pavlos","year":"2012","journal-title":"Pharmacogenomics"},{"key":"R44-4-20210128","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.2217\/pgs.11.131","article-title":"Allopurinol pharmacogenetics: assessment of potential clinical usefulness.","volume":"12","author":"Zineh","year":"2011","journal-title":"Pharmacogenomics"},{"key":"R45-4-20210128","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1056\/NEJMoa0706135","article-title":"HLA-B5701 screening for hypersensitivity to abacavir.","volume":"358","author":"Mallal","year":"2008","journal-title":"N Engl J Med"},{"key":"R46-4-20210128","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1056\/NEJMoa1009717","article-title":"Carbamazepine induced toxic effects and HLA-B1502 screening in Taiwan.","volume":"364","author":"Chen","year":"2011","journal-title":"N Engl J Med"},{"key":"R47-4-20210128","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/clpt.2011.355","article-title":"Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotypes and abacavir dosing.","volume":"91","author":"Martin","year":"2012","journal-title":"Clin Pharm Ther"},{"key":"R48-4-20210128","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/clpt.2012.209","article-title":"Clinical Pharmacogenetics Implementation Consortium guidelines for human leuokocyte antigen-B genotyping and allopurinol dosing.","volume":"93","author":"Hershfield","year":"2013","journal-title":"Clin Pharm Ther"},{"key":"R49-4-20210128","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1365-2133.2012.10965.x","article-title":"The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta-analysis.","volume":"167","author":"Huang","year":"2012","journal-title":"Br J Dermaol"},{"key":"R50-4-20210128","doi-asserted-by":"crossref","first-page":"514","DOI":"10.7326\/0003-4819-151-7-200910060-00016","article-title":"Granulysin as a marker for early diagnosis of the Stevens-Johnson syndrome.","volume":"151","author":"Abe","year":"2009","journal-title":"Ann Intern Med"},{"key":"R51-4-20210128","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jaad.2010.04.042","article-title":"Rapid immunochromatographic test for serum granulysin is useful for the prediction of Stevens-Johnson syndrome and toxic epidermal necrolysis.","volume":"65","author":"Fujita","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"R52-4-20210128","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jaad.2007.08.039","article-title":"Effects of treatment on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR study.","volume":"58","author":"Schneck","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"R53-4-20210128","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/j.1365-2133.2012.11074.x","article-title":"The role of prior corticosteroid use on the clinical course of Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control analysis of patients selected from the multinational EuroSCAR and RegiSCAR studies.","volume":"167","author":"Lee","year":"2012","journal-title":"Br J Dermatol"},{"key":"R54-4-20210128","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/j.1365-2133.2010.09863.x","article-title":"Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis.","volume":"163","author":"Valeyrie-Allanore l, Wolkenstein","year":"2010","journal-title":"Br J Dermatol"},{"key":"R55-4-20210128","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/bjd.12125","article-title":"A multicenter study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions.","volume":"168","author":"Barbaud","year":"2013","journal-title":"Br J Dermatol"},{"key":"R57-4-20210128","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1365-2222.2011.03875.x","article-title":"Poor relevance of a lymphocyte proliferation assay in lamotrigine-induced Stevens-Johnson syndrome or toxic epidermal necrolysis.","volume":"42","author":"Tang","year":"2012","journal-title":"Clin Exp Allergy"},{"key":"R58-4-20210128","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/bjd.12109","article-title":"In vitro diagnostic assays are effective during the acute phase of delayed-type drug hypersensitivity reactions.","volume":"168","author":"Polak","year":"2013","journal-title":"Br J Dermatol"},{"key":"R59-4-20210128","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1365-2222.2011.03701.x","article-title":"In vitro diagnosis of T-cell mediated drug allergy.","volume":"4","author":"Porebski","year":"2011","journal-title":"Clin Exp Allergy"},{"key":"R60-4-20210128","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/clpt.2009.252","article-title":"ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: comparison with case-control analysis.","volume":"88","author":"Sassolas","year":"2010","journal-title":"Clin Pharmacol Ther"}],"container-title":["Current Opinion in Allergy & Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/ACI.0b013e3283630cc2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T16:51:53Z","timestamp":1636563113000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00130832-201308000-00004"}},"subtitle":["the year in review"],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/aci.0b013e3283630cc2","relation":{},"ISSN":["1528-4050"],"issn-type":[{"value":"1528-4050","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]}}}